Day One Biopharmaceuticals

Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.

Jobs:

Clinical Drug Supply Manager (Contract)

San Francisco, CA|21 days ago

Apply

Clinical Trial Specialist (Contract)

San Francisco, CA|21 days ago

Apply

Director, Translational Research

San Francisco, CA|29 days ago

Apply

Vice President Information Technology

San Francisco, CA|47 days ago

Apply

Senior Vice President, External Discovery and Research

San Francisco, CA|100+ days ago

Apply

Chief Commercial Officer

San Francisco, CA|100+ days ago

Apply

Future Opportunities

Open|100+ days ago

Apply